Vaxcyte (NASDAQ:PCVX) Stock: Insider Elvia Cowan Sells 3,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.92, for a total value of $182,760.00. Following the completion of the sale, the chief accounting officer directly owned 27,860 shares of the company’s stock, valued at $1,697,231.20. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan also recently made the following trade(s):

• On Monday, October 5th, Elvia Cowan sold 19,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.74, for a total value of $1,648,060.00.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $61.92 on Friday. Vaxcyte, Inc. has a 52 week low of $40.14 and a 52 week high of $90.75. The stock has a 50 day moving average price of $61.65 and a two-hundred day moving average price of $57.23.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same period last year, the business earned ($1.56) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -7.47 earnings per share for the current year.

Analysts Set New Price Targets

PCVX has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 price objective on shares of Vaxcyte in a report on Monday, October 12th. Needham & Company LLC lifted their price objective on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 5th. Guggenheim lifted their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a report on Monday, October 5th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average price target of $110.50.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. New York Life Investment Management LLC boosted its holdings in shares of Vaxcyte by 19.7% in the 3rd quarter. New York Life Investment Management LLC now owns 21,011 shares of the company’s stock worth $1,196,000 after buying an additional 3,451 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Vaxcyte by 6.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 7,808 shares of the company’s stock valued at $438,000 after buying an additional 444 shares during the period. Candriam S.C.A. increased its holdings in Vaxcyte by 115.0% during the third quarter. Candriam S.C.A. now owns 447,260 shares of the company’s stock worth $25,542,000 after buying an additional 239,206 shares during the last quarter. Covestor Ltd increased its holdings in Vaxcyte by 31.1% during the third quarter. Covestor Ltd now owns 939 shares of the company’s stock worth $53,000 after buying an additional 223 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Vaxcyte in the third quarter worth about $1,270,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.